Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges
Executive Summary
Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.
You may also be interested in...
New Data Means Successful Joint Pricing Talks For Orchard’s Libmeldy in Europe
Orchard Therapeutics has secured reimbursement in Ireland, the Netherlands and Belgium nearly a year after the collapse of joint pricing talks between the company and the three countries.
Hemgenix: European Countries Start Joint HTA Of Another Costly Gene Therapy
CSL’s Hemgenix is the latest expensive gene therapy to come under scrutiny from the BeNeLuxA cross-country coalition.
Ireland, Belgium And The Netherlands Withdraw From Libmeldy Gene Therapy Pricing Talks
The BeNeLuxA medicines access coalition has terminated pricing talks with Orchard over its gene therapy Libmeldy.